Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 2, 2020--First Patient Dosed in Global, Registrational Study of First-in-Class Treatment Candidate--
-
Nov 2, 2020
-
Oct 29, 2020--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020--
-
Oct 28, 2020-- ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition --